Proactive Investors - Run By Investors For Investors

Medical cannabis to be available in UK on prescription by start of November

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis will be among the first to be prescribed the drugs
Cannabis oil
Previously, cannabis-derived medicines could only be prescribed in exceptional circumstances

Medicinal cannabis products, used in the treatment of various conditions that cause chronic pain, will be available on prescription to patients from the start of next month following a rescheduling of the drug by UK Home Secretary Sajid Javid.

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs, which marks a turning point in the push to legalise cannabis products in the UK.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO

At the moment, cannabis-derived can only be prescribed in exceptional circumstances after permission is granted by a panel of medical experts, although the Home Office will relax the rules from 1 November.

The policy change follows an incident in June when 12-year old Billy Caldwell had his cannabis oil, prescribed to alleviate the symptoms of epilepsy, confiscated at Heathrow Airport, a decision that was only reversed when an emergency permit was issued by the government.

However, Geremy Thomas, chief executive and founder of medical cannabis company Sativa Investments PLC (NEX:SATI) said last week that the move by the government is not an indicator that the legalisation of recreational marijuana is in the offing.

Instead, Thomas says things will “become clearer” regarding the details of how the medical cannabis industry in the UK will take shape.

He adds that existing manufacturers outside the UK will likely be awarded limited export licenses for medical cannabis products, with investors “becoming more aware” of the scale of the industry.

“[Investors] will recognise that we [the UK] will be a very significant cannabis market,” he says.

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use